Vedolizumab

Vedolizumab (Entyvio) is a prescription medication used to treat adults with ulcerative colitis (UC) and Crohn's disease (CD). It is a humanized monoclonal antibody that works by blocking a certain protein in the body, thus helping to reduce inflammation in the gastrointestinal tract. It is given as an intravenous (IV) infusion every 8 weeks. Common side effects may include injection site reactions, headache, nausea, and abdominal pain


 

Vedolizumab, sold under the brand name Entyvio, is a medication used to treat specific inflammatory bowel diseases (IBD) (https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/symptoms-causes/syc-20353315). Here's a breakdown of its key features:

  • Conditions it treats:
    • Ulcerative colitis: This is an inflammatory bowel disease causing inflammation and ulcers (sores) in the inner lining of the large intestine (colon).
    • Crohn's disease: This is another inflammatory bowel disease affecting any part of the digestive tract, from the mouth to the anus.
  • Mechanism of action: Vedolizumab works differently from many other medications for IBD. It's classified as an integrin blocker, specifically targeting a protein called alpha-4 beta-7 integrin. This protein plays a role in the migration of immune cells to the inflamed areas in the gut. By blocking this protein, vedolizumab helps reduce inflammation and manage IBD symptoms.
  • Drug class: Integrin receptor antagonist, monoclonal antibody
  • Administration: Vedolizumab is given by intravenous (IV) infusion, typically in a healthcare setting.

Here's some additional information about vedolizumab:

  • Benefits: It can help induce and maintain remission (reduced disease activity) in patients with moderate to severe ulcerative colitis or Crohn's disease who haven't responded adequately to other medications.
  • Potential side effects: As with any medication, vedolizumab can cause side effects. Some common ones include headache, fever, fatigue, upper respiratory tract infections, and injection site reactions. It's important to discuss potential side effects with your doctor before starting treatment.
  • Important considerations: Vedolizumab may affect the immune system, so it's crucial to inform your doctor about any infections you have or have recently had.
Anatomical Therapeutic Chemical Classification
L - Antineoplastic and immunomodulating agents
L04 Immunosuppressants
L04A - Immunosuppressants
L04AA Selective immunosuppressants
External Links